Document is current
Any future updates will be listed below
-
Authors
Nair, Viji
Minakawa, Akihiro
Smith, Cathy https://orcid.org/0000-0003-1518-9320
Berthier, Celine C.
Hartman, John
Menon, Rajasree
Fermin, Damian
Otto, Edgar A.
Gisch, Debora L. https://orcid.org/0000-0001-9087-4585
Eadon, Michael T. https://orcid.org/0000-0003-3066-2876
Jain, Sanjay https://orcid.org/0000-0003-2804-127X
Choi, Ye Ji
Pyle, Laura
Eichinger, Felix
Alakwaa, Fadhl M.
Rose, Michael P. https://orcid.org/0000-0001-8661-5134
Subramanian, Lalita
El Saghir, Jamal https://orcid.org/0000-0002-3779-4583
Beamish, Jeffrey A.
Hodgin, Jeffrey B.
Brosius, Frank C. https://orcid.org/0000-0002-4244-8335
Bjornstad, Petter
Nelson, Peter J.
Harder, Jennifer L. https://orcid.org/0000-0002-7927-608X
Werner, Thomas
Kretzler, Matthias
Schaub, Jennifer A.
- License Information
-
More Information
Article History
Received: 16 October 2025
Revised: 22 January 2026
Accepted: 13 February 2026
First Online: 21 April 2026
Competing interests
: P.B. reports serving or having served as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli-Lilly, LG Chemistry, Sanofi, Novo Nordisk, and Horizon Pharma. P.B. also serves or has served on the advisory boards and/or steering committees of AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, Lilly, and XORTX. P.B. serves as DMC Chair for Bayer and a DMC member for Cytel. P.B. reports grant funding from AstraZeneca, Novo Nordisk, Eli Lilly, Boehringer-Ingelheim, Merck, and Amgen/Horizon Pharma. M.K. reports grants and contracts through the University of Michigan outside of this work from Chan Zuckerberg Initiative, AstraZeneca, NovoNordisk, Eli Lilly, Boehringer-Ingelheim, European Union Innovative Medicine Initiative, Certa Therapeutics, RenalytixAI, Regeneron, Novo Nordisk, Sanofi, Dimerix, Travere and Vera Therapeutics. M.K. has received consulting fees through the University of Michigan from NovoNordisk, Alexion, Novartis, Roche Diagnostics and Vera Therapeutics. In addition, M.K. and V.N. have a patent, PCT/EP2014/073413 “Biomarkers and methods for progression prediction for chronic kidney disease” licensed. All other authors do not have conflicts to report.
